Younger Patients with Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors Seem to be Prone to Return to Work

In this MEDtalk, Edyta Maria Urbanska presents new real-world data on Danish patients with rearranged non-small lung cancer. One of the clinical messages from the study is that the second generation of ALK tyrosine kinase inhibitors was more effective than crizotinib. The study also shows that the majority of patients lose affiliation to the labor market, but younger patients treated with ALK tyrosine kinase inhibitors seem to be prone to return to work.